NVS Novartis Corporation: Enterprise Value-to-Revenue Multiple

Novartis Corporation (NVS) - corporate logo

Novartis AG (NVS) focuses on innovative medicines, remaining dependent on FDA verdicts. This strategy is bolstered by the brand's authority among global medical professionals and an academic culture that attracts leading biochemists. The company's price-to-sales ratio visualizes the market valuation of the asset, while 5717.56 represents the latest level, helping to determine the objectivity of current quotes.

Novartis Inc. (NVS) - EV/Sales Multiple from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for Novartis (NVS)

- share price and consensus valuation forecast:
Fundamental company valuation:NVS (novartis.com)
Product sample of novartis.com

Institutional capital utilizes this indicator to determine the market overvaluation of Novartis AG relative to its operational scale. The enterprise value-to-revenue ratio combines market capitalization and net debt, allowing for an assessment of the actual cost of acquiring the business inclusive of its debt load. For this pharmaceutical behemoth, this metric reflects the efficiency of monetizing patented developments in oncology and cardiology, confirming the asset's fundamental stability.